Comparative Pharmacology
Head-to-head clinical analysis: COLESTID versus LOCHOLEST LIGHT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COLESTID versus LOCHOLEST LIGHT.
COLESTID vs LOCHOLEST LIGHT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in the feces, thereby increasing fecal loss of bile acids and reducing enterohepatic circulation of bile salts. This leads to increased hepatic conversion of cholesterol to bile acids, reduction in hepatic cholesterol stores, and decreased plasma LDL cholesterol levels.
Locholest Light is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and decreased serum LDL cholesterol.
5-10 g orally once or twice daily, maximum 30 g/day.
LOCHOLEST LIGHT is not a recognized drug name. No data available.
None Documented
None Documented
Not applicable due to non-systemic action; local gastrointestinal half-life not clinically defined
Terminal elimination half-life is approximately 19-24 hours; due to enterohepatic recirculation, effective half-life may be extended. Steady state is achieved within 4-6 weeks with continuous dosing.
Primarily fecal (≥95%) as unchanged drug; minimal renal excretion (<5%)
Primarily biliary/fecal (approximately 75% as metabolites, <10% unchanged drug in feces); renal excretion accounts for about 20% of total elimination (mainly as inactive metabolites).
Category C
Category C
Bile Acid Sequestrant
Bile Acid Sequestrant